Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.60 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.56 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101455 | 0.95 | CYP2D6 (0.64) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL1741576 | 0.89 | MEN1 (0.74) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL11203267 | 0.85 | HTT (0.59) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| Norchlorcyclizine SCHEMBL6556514 | 0.85 | CYP2D6 (0.86) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| Norchlorcyclizine SCHEMBL588655 | 0.85 | CYP2D6 (0.86) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| Norchlorcyclizine SCHEMBL467086 | 0.85 | CYP2D6 (0.86) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL219432 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| SCHEMBL2794662 | 0.85 | MEN1 (1.00) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| Norchlorcyclizine SCHEMBL4649874 | 0.84 | CYP2D6 (0.83) | MEN1KMT2ACYP2D6CYP19A1OPRD1 | |
| Norchlorcyclizine SCHEMBL588155 | 0.84 | CYP2D6 (0.83) | MEN1KMT2ACYP2D6CYP19A1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| WO-2011148888-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | あすか製薬株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
| EP-1020443-B1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | AZWELL INC (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-6172228-B1 | Process for producing piperazinesulfonamide derivatives and salts thereof | AZWELL INC. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1020443-A1 | PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF | Azwell Inc. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-4377578-A | ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1983-03-22 | — | — | US | disclosed |
| US-4252804-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | METABIO-JOULLIE (FR) | 1981-02-24 | — | — | US | disclosed |
| US-4252804-A | TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS | METABIO-JOULLIE (FR) | 1981-02-24 | — | — | US | disclosed |
| US-4250176-A | BENZIMIDAZOLE-2-ONE, BENZOTHIAZOL-2-ONE, OR BENZOXAZOL-2-ONE SUBSTITUTIONS, ANTIANAPHALACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-02-10 | — | — | US | disclosed |
| US-4200641-A | ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | MEN1 2318/4885KMT2A 524/4885CYP2D6 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.